- Home
- Publications
- Publication Search
- Publication Details
Title
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume -, Issue -, Pages -
Publisher
Massachusetts Medical Society
Online
2023-06-05
DOI
10.1056/nejmoa2304594
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
- (2023) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2
- (2023) Yasuhiro Tsutani et al. Clinical Lung Cancer
- Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
- (2023) Thomas John et al. Journal of Thoracic Oncology
- 91P Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study
- (2023) S. Lin et al. Journal of Thoracic Oncology
- Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials
- (2023) Ning Zhao et al. World Journal of Surgical Oncology
- Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
- (2022) Margarita Majem et al. CLINICAL CANCER RESEARCH
- Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
- (2022) Katherine Pisters et al. JOURNAL OF CLINICAL ONCOLOGY
- Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
- (2022) Jia-Tao Zhang et al. Cancer Discovery
- Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials
- (2022) Marco de Scordilli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
- (2021) J. Remon et al. ANNALS OF ONCOLOGY
- FDA Approval Summary: Osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review
- (2021) Abigail L. Koch et al. CLINICAL CANCER RESEARCH
- Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
- (2021) Masahiro Tsuboi et al. Future Oncology
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- (2021) Enriqueta Felip et al. LANCET
- Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
- (2021) Jianxing He et al. Lancet Respiratory Medicine
- Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy
- (2021) Toshiaki Takahashi et al. CANCER SCIENCE
- The Role and Impact of Minimal Residual Disease in NSCLC
- (2021) Daniele Frisone et al. Current Oncology Reports
- The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy
- (2020) Carlos Galvez et al. Oncotarget
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
- (2019) James C.H. Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
- (2019) Myung-Ju Ahn et al. Journal of Thoracic Oncology
- ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
- (2018) Yi-Long Wu et al. Clinical Lung Cancer
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Thanyanan Reungwetwattana et al. JOURNAL OF CLINICAL ONCOLOGY
- The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
- (2018) Song-Tao Xu et al. Journal of Thoracic Oncology
- Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is ‘cured’ from postoperative recurrence?
- (2017) Keigo Sekihara et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
- (2017) Mark G. Kris et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical and Pathological Staging Validation in the Eighth Edition of the TNM Classification for Lung Cancer: Correlation between Solid Size on Thin-Section Computed Tomography and Invasive Size in Pathological Findings in the New T Classification
- (2017) Keiju Aokage et al. Journal of Thoracic Oncology
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer
- (2016) Solange Peters et al. CANCER TREATMENT REVIEWS
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- (2016) Peter Goldstraw et al. Journal of Thoracic Oncology
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
- (2015) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters
- (2014) Solange Peters et al. Journal of Thoracic Oncology
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search